REG - Diaceutics PLC - Expanded lab network and data capabilities

DiaceuticsAnnouncement

27/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240227:nRSa5258Ea&default-theme=true

RNS Number : 5258E  Diaceutics PLC  27 February 2024

Diaceutics grows its lab network and data capabilities in Europe

 

New data will deliver enhanced insights to Diaceutics' customers and drive new
sales opportunities across multiple geographies

 

Belfast and London, 27 February 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, is
pleased to announce it has expanded its data supply network which will
significantly increase the number of labs through which Diaceutics is sourcing
data in Europe and will broaden the Company's European data coverage. This
data will accelerate the rollout of the DxRx Signal product in key EU markets
of Germany, France, Italy, Spain and the United Kingdom (DxRx Signal has only
previously been offered by Diaceutics in the US market).

The increased data is now available to Diaceutics customers enabling them to
find more patients eligible for their new and innovative therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "This data will
further endorse our position as a leading provider of data to biotech and
pharma companies as they commercialize their products, find and deliver
therapies to patients across multiple geographies."

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of MAR. The person responsible
for making this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.

 

Enquiries:

 Diaceutics PLC                                          Tel: +44 (0)28 9040 6500
 Ryan Keeling, Chief Executive Officer                  investorrelations@diaceutics.com

 Nick Roberts, Chief Financial Officer

 Jordan Clark, Chief Data Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland

 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44 (0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDXGDDDBDDGSL